The convertible note offering provides $243M in net cash to fund operations and pipeline development, reducing near-term financing risk. However, potential dilution of up to ~13.6M shares (roughly 8-10% of current shares outstanding based on $1.6B market cap) creates overhang. Monitor the stock price relative to the $24.76 conversion price — if SNDX trades above that level, conversion risk increases. The 2.25% coupon is low-cost debt for a biotech, but the 35% premium suggests management sees upside. Watch for the closing on June 10 and any subsequent use-of-proceeds announcements.
Price Chart
Executive Summary
Syndax Pharmaceuticals entered into subscription agreements to issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in a private placement, expected to close on June 10, 2026. Net proceeds of approximately $243 million will be used for general corporate purposes including R&D, commercialization, and business development. The notes carry a 35% conversion premium over the June 3 closing price and are senior unsecured obligations maturing in 2031.
Key Financial Metrics
Key Facts
- $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031
- Net proceeds estimated at approximately $243 million
- Initial conversion price of approximately $24.76 per share, a 35% premium over the last reported sale price on June 3, 2026
- Notes mature June 15, 2031, interest payable semi-annually at 2.25%
- Company may not redeem notes prior to June 20, 2029
- Maximum of 13,631,400 shares of common stock issuable upon conversion based on initial maximum conversion rate
- Sale expected to close June 10, 2026, subject to customary closing conditions
- J. Wood Capital Advisors LLC acting as sole placement agent
Financial Impact
$250M principal raised, ~$243M net proceeds after fees and expenses
Risk Factors
- Potential dilution of up to 13.6M shares upon conversion, representing meaningful overhang
- Interest expense of ~$5.6M annually adds fixed cost to a commercial-stage biotech still scaling revenue
- If stock price declines, notes could still be converted under alternative conditions (trading price <98% of parity), accelerating dilution
- Proceeds used for general corporate purposes provides limited visibility on capital allocation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-256458 |
| Document: d65010d8k.htm | 0001193125-26-256458 |
| Document: d65010dex991.htm | 0001193125-26-256458 |
| Document: 0001193125-26-256458-index-headers.html | 0001193125-26-256458 |
| Document: 0001193125-26-256458-index.html | 0001193125-26-256458 |
| Document: 0001193125-26-256458.txt | 0001193125-26-256458 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 14, 2026 11w ago | 8-K | $24.13 $20.29 | ▼ −15.91% | ▼ −18.41% | $17.60 (−27.06%) |
Jul 1, 2026 13w ago | Press Release | $21.82 $19.48 | ▼ −10.72% | ▼ −10.31% | $17.60 (−19.34%) |
Jun 11, 2026 16w ago | Press Release | $17.91 $24.84 | ▲ +38.69% | ▲ +36.80% | $17.60 (−1.73%) |
Jun 10, 2026 16w ago | 8-K | $17.91 $24.84 | ▲ +38.69% | ▲ +36.80% | $17.60 (−1.73%) |
Jun 4, 2026 17w ago | Press Release | $17.34 $22.08 | ▲ +27.34% | ▲ +25.47% | $17.60 (+1.50%) |
Jun 4, 2026 17w ago | DEFA14A | $18.02 $21.82 | ▲ +21.09% | ▲ +22.46% | $17.60 (−2.33%) |
Jun 4, 2026 17w ago | 8-K | $18.02 $21.82 | ▲ +21.09% | ▲ +22.46% | $17.60 (−2.33%) |
Apr 30, 2026 22w ago | DEFA14A | $19.11 $18.85 | ▼ −1.36% | ▼ −6.64% | $17.60 (−7.90%) |
Apr 24, 2026 23w ago | Press Release | $21.39 $19.77 | ▼ −7.57% | ▼ −11.60% | $17.60 (−17.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access